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Maternal serum screening for neural tube defects and fetal aneuploidy in the second trimester has been
incorporated into obstetrical practice over the past two decades. Now, as a result of several multicenter trials, first
trimester screening between 11 and 14 weeks has been shown to be an effective and reliable screening test for
Down syndrome and trisomy 18. Benefits of first trimester screening include earlier identification of the pregnancy
at risk for fetal aneuploidy and anatomic defects, in particular, cardiac anomalies, and the option of earlier
diagnosis by chorionic villus sampling, if available. This policy updates the American College of Medical Genetics
policy statement entitled Second Trimester Maternal Serum Screening for Fetal Open Neural Tube Defects and
Aneuploidy (2004) and complements the sections of American College of Medical Genetic’s Standards and
Guidelines for Clinical Genetics Laboratories entitled “Prenatal screening for Down syndrome that includes first
trimester biochemistry and/or ultrasound measurements.” Genet Med 2008:10(1):73–75.
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Disclaimer:Thisguidelineisdesignedprimarilyasaneducationalresourceformedicalgeneticistsandotherhealthcareproviders
to help them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a successful medical
outcome. This guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and
tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the
geneticistshouldapplyhisorherownprofessionaljudgmenttothespecificclinicalcircumstancespresentedbytheindividualpatient
or specimen. It may be prudent, however, to document in the patient’s record the rationale for any significant deviation from this
guideline.
Maternal serum screening for neural tube defects and fetal
aneuploidyhasbecomepartofcurrentobstetricalpractice.For
over two decades, the focus of such screening programs was
based in the second trimester. However, as a result of several
multicentered studies conducted in the United States and
abroad, first trimester screening between 11 and 14 weeks has
been demonstrated to be a useful and reliable option for preg-
nant women.1–4 Benefits of early screening include potentially
earlier diagnosis, thereby improving women’s reproductive
choices, and more accurate pregnancy dating. Although
screening for Down syndrome (DS) remains the driving force
behind this modality, screening in the first trimester also has
thepotentialtoidentifyotheraneuploidiessuchasTrisomy18.
The addition of ultrasound also allows for the early detection
ofanatomicdefects,particularlycardiacinorigin.Thiscurrent
policy updates the American College of Medical Genetics
(ACMG)policystatemententitledSecondTrimesterMaternal
Serum Screening for Fetal Open Neural Tube Defects and
Aneuploidy (2004) and complements the sections of ACMG’s
Standards and Guidelines for Clinical Genetics Laboratories
entitled “Prenatal screening for Down syndrome that includes
first trimester biochemistry and/or ultrasound measure-
ments.”
DIAGNOSIS OF FETAL ANEUPLOIDY
Although there is exciting research and innovation in the
field of noninvasive testing for fetal aneuploidy, at present
there are two tests, both invasive, which are used in a routine
manner to determine the presence of fetal aneuploidy—
chorionic villus sampling (CVS) and amniocentesis. CVS is
performed in the first trimester from 10 through 13 weeks’
gestation, whereas amniocentesis can be performed starting at
15 weeks’ gestation. More recent literature suggests that the
risk of pregnancy loss from sonographically directed amnio-
centesisis1in300–600,5,6withonestudysuggestingthatthere
may be no significant increase over the background miscar-
riagerisk.7Likewise,theriskofpregnancylosswithCVSisalso
low, particularly for transabdominal procedures.8 Transcervi-
cal CVS loss rates are slightly increased. Based on the relative
safety of these diagnostic procedures, and in deference to pa-
tient preference and autonomy, the American College of Ob-
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Genetics IN Medicine 73stetricians and Gynecologists recently recommended that all
pregnant women regardless of maternal age should have the
option of having an invasive diagnostic test to definitively
identify not only DS, but all major fetal aneuploidies. Such
diagnostic testing should be made available if requested after
appropriate counseling including risks and benefits. Likewise,
women who do not want any further information regarding
chromosomal status of their fetus should not be required to
undergo any further testing or screening. Screening provides
such an option for those women who would like to further





demonstrated utility are pregnancy-associated plasma protein
A (PAPP-A), which is typically reduced and human chorionic
gonadotrophin (hCG), which is elevated in DS. The overall
data suggest that free beta hCG is likely superior.9 However,
access to free beta hCG has been limited and, therefore, many
programs in the United States use intact hCG.
Ultrasound
The big breakthrough in first trimester screening was the
advent of the nuchal translucency (NT) measurement. Be-
tween 11 and 14 weeks, a clearly demarcated fluid-filled space
can be seen behind the fetal neck. This space is present in all
fetuses. An increased NT measurement is significantly associ-
ated with fetal DS and other aneuploidies. The detection rate
for DS is approximately 70% with a 5% false-positive rate.
Other sonographic findings are being investigated as potential
markers for DS. Absence of the nasal bone is associated with
DS but its value as a screening test in the general population is
controversial. As with the NT measurement, standardization
of the technique and quality assessment programs are essen-
tial.10 Some programs have incorporated nasal bone assess-
ment into their first trimester screening protocol.11 Now there
is also substantial evidence that congenital heart defects may
present with increased NT measurement.12 Other findings as-
sociated with increased NT measurements include diaphrag-
matic hernias, skeletal dysplasias, and a variety of genetic syn-
dromes.10 Based on the current scientific evidence, the
American College of Obstetricians and Gynecologists recom-
mendsthatpatientswithafetalNTmeasurementof3.5mmor
higher be offered a targeted ultrasound, echocardiogram, or
both.
Combined ultrasound and serum markers
Multiple studies have demonstrated that the most effective
DSscreeningapproachinthefirsttrimesteristhecombination
of maternal age, NT measurement, and serum markers. The
DS detection rates in four major studies range from 79 to 90%
with a 5% false-positive rate. A consistent finding across all
studiesisthenecessityforstandardizationandrigorousquality
control both in the laboratory assays and NT measurements.
Combined algorithms are also available for Trisomy 18.13 It is
acknowledgedthatcombinedultrasoundandserumscreening
formultifetalgestationsremainslesssensitivethaninsingleton
pregnancies. There are insufficient prospective studies to de-
termine actual detection rates so that laboratories that do pro-
vide risk results are using mathematical models. There is also
the ongoing concern that serum marker levels reflective of
both pregnancies are actually averaged, which is a problem
across all trimesters. NT measurement alone is useful in
screening multiple gestations for DS but is associated with a
higher positive screening rate.
SCREENING IN BOTH FIRST AND SECOND TRIMESTERS
There have been several different approaches to improve
screening rates based on combining first and second trimester
screening. These include integrated testing, where NT mea-
surementandPAPP-Ainthefirsttrimesterarecombinedwith
the second trimester screening that includes alphafetoprotein,
hCG, unconjugated estriol, and dimeric inhibin-A; however,
with this approach results are not available until the second
trimester.14 Sequential screening takes advantage of the higher
detection rates achieved with an integrated approach but dis-
closes the first trimester results, which allows a patient the op-
tion of CVS and earlier termination in the event of an affected
fetus. Independent assessment of DS risk by both first and
second trimester screening is discouraged because of the high
false-positive rates associated with this approach.15 Most re-
cently,contingencyscreeninghasbeenproposedwherebyonly
those women with a result in a predefined intermediate range
undergo testing in the second trimester.16 These various com-





● All women should have the option of invasive diagnostic
testingforfetalaneuploidybyCVS,ifavailable,oramnio-
centesis. Benefits include diagnosis of all major aneu-
ploidies and large chromosomal rearrangements.
● For women who do not want any information regarding
fetal aneuploidy status, following appropriate documen-
tation, no other testing or screening is required.
● First trimester screening (NT, PAPP-A, and hCG) is an
acceptable, cost effective approach for DS risk screening
for women if they present early in pregnancy (before 14
weeks’ gestation).
● Incorporation of the nasal bone assessment into the first
trimester screening protocol is optional and should be
limited to clinicians who have specific training and par-
ticipate in an ongoing quality assurance program.
First Trimester Screening
74 Genetics IN Medicine● Women presenting in the second trimester should be of-
fered multiple marker screening as described in the
ACMG policy statement entitled Second Trimester Ma-
ternal Serum Screening for Fetal Open Neural Tube De-
fects and Aneuploidy (2004) (www.acmg.net).
● Approaches that use first and second trimester screening
have improved detection rates and lower false-positive
rates. However, providers and centers must be prepared
toensurethatthereisadequatefollow-upandnondisclo-
sure is acceptable to the patient if they choose to offer
integratedscreening.Sequentialorcontingencyscreening
with disclosure of the first trimester results may be pref-
erable for some providers and patients.
● Women should be informed of the adjusted risk for DS
and allowed to make decisions based on this number, be-
cause individuals will weigh risk/benefits differently and
are capable of such decision-making. Because age is no
longer used as a cutoff to offer invasive testing, it is no
longer logical to use predetermined cutoffs based on age
risk for screening programs.
● First trimester screening can be used in multifetal preg-
nancies; however, women should be made aware of the
limitations of screening in this setting.
● An NT measurement of 3.5 mm or greater, even in the
settingofalowriskforaneuploidyscreenresultornormal
fetal karyotype should prompt a detailed anatomic ultra-
sound, echocardiogram, or both.
● Womenwhohaveelectedtohavefirsttrimesterscreening
and/or CVS should be offered MSAFP screening and/or
an anatomic survey, optimally between 16 and 20 weeks’
gestation for the detection of neural tube defects.
● Firsttrimesterscreeningrequiresadherencetostrictstan-
dards and maintenance of quality, both in the laboratory
and ultrasound units. Sonographers must be appropri-
atelytrainedinthepropertechniqueofNTmeasurement
and have appropriate certification through available or-
ganizations.
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